138 results about "Endometrioses" patented technology

The present invention relates, inter alia, to compounds having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —NC4H8, —NC5H10, —NC4H8O, —CHO, —CH(OH)CH3, —C(O)CH3, —O(CH2)2N(CH3)2, and —O(CH2)2NC5H10; R2 is a member selected from the group consisting of hydrogen, halogen, alkyl, acyl, hydroxy, alkoxy (e.g., methoxy, ethoxy, vinyloxy, ethynyloxy, cyclopropyloxy, etc.), acyloxy (e.g., acetoxy, glycinate, etc.), alkylcarbonate, cypionyloxy, S-alkyl, —SCN, S-acyl and —OC(O)R6, wherein R6 is a functional group including, but not limited to, alkyl (e.g., methyl, ethyl, etc.), alkoxy ester (e.g., —CH2OCH3) and alkoxy (—OCH3); R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl.In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce cervical ripening; to induce labor; and for contraception.

The present invention relates to a combination of resveratrol with progestogen, and medicaments and pharmaceutical compositions containing the same, which are useful in the treatment and / or prevention of myoma and / or endometriosis, providing their size reduction and the control of related symptoms. Said association may additionally comprise an estrogen component. A treatment method and a kit are also objects of this invention.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

A medicament for the preventive and / or therapeutic treatment of allergic diseases and / or endometriosis and / or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The present invention relates to compound of Formula Ior pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula I as IDO1 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and / or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula I.

To provide a novel and excellent method for treating and / or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5.It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and / or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

The present invention refers to a group of biomarkers and to non-invasive in vitro methods for the diagnosis or prognosis of endometriosis, as well as to a kit to perform said methods.

The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided.

The invention relates to methods and a kit for the diagnosis of endometriosis. More particularly, the invention relates to the measurement of endometrial leukocytes bearing CD16b and, optionally, other leukocyte or serous markers, for determining likelihood of suffering from endometriosis in a female subject.

The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided.

The fixed extended cycle method of female hormonal contraception includes continuous daily administration of daily dosage units of a monophasic preparation to a woman over a time period of n×21 days, wherein n=2, 3, 4 or 5, immediately followed by a seven-day pill-break in which the monophasic preparation is not administered. Each of the daily dosage units contains from 0.5 to 3.0 mg of dienogest and from 10 to 30 μg of ethinyl estradiol. In addition to effective contraceptive action the method significantly reduces the bleeding rate, is simple and is effective in treating acne, dysmenorrhea and / or endometriosis.

The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.

The invention discloses a Chinese medicine composition for treating endometriosis uterine, belonging to the technical field of Chinese medicine, which is characterized in that a plurality of medicinal herbs, such as radix salviae miltiorrhizae, motherwort, Rhizoma Zedoariae, semen coicis, dragon's blood are used as raw materials, and undergo the processes of alcohol extraction and water extraction according to relevant compatibility requirements, so as to produce the intended medicine preparation, and the Chinese medicine composition is optimally manufactured into capsules. The Chinese medicine composition has an advantage of remarkable curative effect for endometriosis uterine.

The invention relates to a pharmaceutical combined preparation of LHRH analogues and anti-oestrogens having tissue-selective oestrogen activity and also to its use for the treatment of gynaecological disorders, especially for the treatment of endometrioses and myomas.

The invention relates to a drug for treating endometriosis, in particular to TCM (Traditional Chinese Medicine) oral solution for treating endometriosis, which is made by adopting plants and herbal medicine as raw materials. The invention adopts the technical scheme as follows: the TCM (Traditional Chinese Medicine) oral solution for treating endometriosis comprises following crude drugs according to the parts by weight: 3 to 12g of Radix Bupleuri, 3 to 8g of Radix Salviae Miltiorrhizae, 3 to 12g of Radix Angelicae Sinensis, 3 to 12g of Semen Persicae, 3 to 12g of Flos Carthami, 3 to 12g of Rhizoma Sparganii, 3 to 12g of Rhizoma Curcumae, 3 to 8g of Radix Glycyrrhizae 3 to 8, 3 to 12g of Radix Cyathulae, 5 to 15g of Radix Paeoniae Rubra and 3 to 8g of Rhizoma Chuanxiong. The TCM (Traditional Chinese Medicine) oral solution for treating endometrios is compounded to benefit mutually, and has the effects of promoting qi and blood flows, removing heat evil and toxic substances, eliminating stagnation and relieving pains, removing heat from blood and relieving swelling, relieving restlessness and tranquilizing the mind and alleviating constipation. The TCM is taken orally to achieve the functions of regulating the physiological functions, strengthening the body resistance to consolidate the constitution, adjusting endocrine disorders, enhancing immune function, keeping the balance of Yin and Yang and restoring dynamic balance of functions of the internal organs, so as to effectively treat endometriosis. The TCM (Traditional Chinese Medicine) oral solution for treating endometriosis has no adverse effect, is economical and can be made home with ease; and is applied to the treatment of pelvic diseases such as endometrial nodules or ovarian chocolate cyst.

A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl. In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.

The invention relates to the field of traditional Chinese medicines, in particular to an external traditional Chinese medicine composition for relieving chronic pelvic pain and dysmenorrheal caused by endometriosis. The external traditional Chinese medicine composition is prepared from the following raw herbal materials in part by weight: 6-12 parts of radix aconiti preparata, 6-12 parts of folium artemisiae argyi, 20-40 parts of spatholobus suberctu, 10-20 parts of Cortex Illicii, 10-30 parts of saposhnicovia divaricata, 10-30 parts of cortex acanthopanacis, 10-20 parts of radix angelicae, 10-20 parts of lycopodium clavatum, 10-20 parts of flos carthami, 10-20 parts of notopterygium root, 10-20 parts of radix angelicae pubescentis and 10-20 parts of speranskia tuberculata. The external traditional Chinese medicine composition has the advantages that effects of warming the channel and dispersing cold, promoting blood circulation to remove blood stasis, relieving swelling and pain and the like are achieved, according to clinical application for many years and pharmacological study, chronic pelvic pain and dysmenorrheal caused by endometriosis can be relieved obviously, effects are remarkable, and the external traditional Chinese medicine composition is economical and convenient, is low in side effect, has an obvious curative effect, does not have toxic or side effects, is low in cost, and is convenient to popularize and use.

The present invention is one kind of medicine for treating endometriosis and its preparation process. The medicine is dispersant tablet comprising medicinal material megestrol acetate and corresponding supplementary material, and may be also prepared into other pharmaceutically acceptable forms, such as pill, common tablet, granule, oral liquid, etc. The medicine has obvious curative effect on endometriosis, stable quality, and other advantages.

High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and lnsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide. Relaxin has also been used in the treatment of severe chronic pain, particularly pain arising from stretching, swelling, or dislocation of tissues.

The invention relates to a drug used for treating endometriosis. The drug is prepared by the following raw materials by weight: 2.80-3.20 parts of pieplant, 2.80-3.20 parts of turtle shell, and 1.30-1.70 parts of amber. The invention discloses a method of producing the drug used for treating endometriosis. The drug has the functions of dissipating blood stasis and purging the bowels, is mainly used for treating endometriosis the indications of which are dysmenorrhea, pelvic pain, straining feeling in anus, sore waist and constipation, dark tongue or with ecchymosis, thin tongue coating, thready pulse or pulse string small. Compared with the western medicine danazol, the invention has similar clinical curative effects but with fewer adverse effects and can be easily accepted by patients.

The invention provides a pharmaceutical composition for treating endometriosis (EMT) and adenomyosis (AM). The pharmaceutical composition is a preparation prepared from the following raw pharmaceutical materials in parts by weight: 80-120 parts of sargentgloryvine stem, 80-120 parts of barbat skullcap, 40-60 parts of rhubarb root, 40-60 parts of peach kernels, 40-60 parts of ground beetle, 40-60 parts of leeches, 60-90 parts of rhizoma sparganii, 60-90 parts of zedoary, 60-90 parts of turtle shell, 80-120 parts of oyster shell, 60-90 parts of Zhejiang fritillary bulb and 80-120 parts of coix seed. The invention further provides a preparation method and use of the pharmaceutical composition. Drugs prepared from the pharmaceutical composition are used for treating EMT and AM, are definite in drug effect and have the advantages of stable quality, convenience in carrying, easiness in storage and convenience in batch production compared with traditional Chinese medicine decoctions; clinical application is better facilitated, the tolerability and acceptability to the drugs of patients are improved, difficult problems in the treatment of EMT and AM by using the decoctions at present are solved, the clinical treatment effect is further improved, professional special-disease traditional Chinese medicine treatment characteristics are strengthened, and a new option is provided for the clinical treatment of EMT and AM.

The invention relates to a preparation method and a quality control method of a new drug, Danazol Vaginal Tablets, for treating endometriosis with clear dysmenorrhea symptom but light physical sign. The drug can be delivered via cavitary mucosa, so as to prevent or relieve the possible adverse reactions due to systemic drug delivery; the effective drug concentration at lesion site is high, so as to be in favor of exert curative action; and the added lactic acid-calcium lactate buffer system results in the drug with pH of 3.5-4.0 that is similar to the physiological pH in vagina, so as to effectively retain physiological environment in vagina, provide existing conditions suitable for vaginal beneficial bacteria, and promote rehabilitation.

Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy.